SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

SanDisk ($SNDK) is trending due to its inclusion in the S&P 500, replacing Interpublic Group ($IPG), sparking bullish sentiment. The community is discussing whether the recent surge is justified, with some anticipating a pullback while others foresee continued upward momentum towards $300. Analysts' price target increases and reported undersupply in the NAND market are also fueling the conversation.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is trending as investors digest the implications of its oral semaglutide failing to meet endpoints in Alzheimer's trials, leading to a significant stock drop. The community is debating whether this sell-off is an overreaction, considering the company's continued dominance in the weight loss market and the potential approval of its oral Wegovy. Some investors view the dip as a buying opportunity, while others express concern about the company's future prospects amidst increasing competition.

Carnival Corp. engages in the operation of cruise ships. It operates through the following business segments: North America and Australia (NAA) Cruise, Europe and Asia (EA) Cruise Operations, Cruise Support, and Tour and Others. The North America and Australia (NAA) Cruise segment includes the Carnival Cruise Line, Holland America Line, Princess Cruises, and Seabourn. The Europe and Asia (EA) Cruise Operations segment consists of AIDA, Costa, Cunard, and P&O Cruises (UK). The Cruise Support segment represents port destinations and private islands for the benefit of its cruise brands. The Tour and Other segment operates hotel and transportation operations of Holland America Princess Alaska Tours. The company was founded in 1972 and is headquartered in Miami, FL.

Carnival Corp. - Ordinary Shares (Paired Stock)

Carnival Corp

Cruise line stocks, including CCL, experienced a sudden drop, leaving traders searching for a clear catalyst. Community discussions highlight concerns about cautious outlooks on the U.S. macroeconomic environment and potential headwinds from Caribbean capacity growth. Some traders are pointing to possible manipulation, while others are looking for a buying opportunity amid the uncertainty.

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Chatham, NJ.

Tonix Pharmaceuticals Holding Corp

TNXP is trending as the community discusses the company's future prospects following the commercial launch of Tonmya, with some questioning its potential impact amidst concerns of dilution.  Bulls express optimism about the new drug and potential for a short squeeze, while bears cite concerns about the company's history and financial management. Discussions also include institutional ownership, possible buyback, and potential buyout.

Zoom Communications, Inc. engages in the provision of a communications and collaboration platform. It operates through the following geographical segments: Americas, Asia Pacific, and Europe, Middle East, and Africa. The company was founded by Eric S. Yuan in 2011 and is headquartered in San Jose, CA.

Zoom Communications Inc. - Ordinary Shares - Class A

Zoom Video Communications, Inc.

Zoom ($ZM) is trending as the community discusses its potential for AI-driven growth following recent earnings and analyst ratings updates, despite concerns about market competition and historical performance. Community talking points revolve around its cash reserves, innovation, and potential acquisitions. Broader discussions involve whether Zoom can move beyond its pandemic-era association and solidify its position in the UCaaS landscape.

Symbotic, Inc. is an automation technology company, which engages in a robotics and automation-based product movement technology platform. It focuses on developing, commercializing, and deploying innovative, end-to-end technology solutions for supply chain operations. It operates through the United States and Canada geographical segments. The company was founded by Richard B. Cohen on December 11, 2020 and is headquartered in Wilmington, MA.

Symbotic Inc - Ordinary Shares - Class A

Symbotic Inc 

Symbotic is trending following its Q4 earnings release, with community members weighing the positive revenue growth against concerns about valuation and customer concentration. Discussions also include the company's long-term potential in warehouse automation and the impact of recent shifts in risk factors, including retail dependency and supply chain vulnerabilities. Bullish sentiment remains, with some anticipating a continued rise and potential short squeeze.

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Altimmune Inc

Altimmune is trending as investors discuss potential data integrity concerns from a recent trial and its implications for future FDA meetings. Community members are debating the validity and impact of the data, with some suggesting a possible buyout or partnership on the horizon. The stock's movement is also influenced by competitor activity and discussions around potential acquisition targets.

Galectin Therapeutics, Inc. is a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease, severe skin disease, and cancer. Its programs target the development of carbohydrate molecules which offers alternative options to larger market segments. The company was founded by James C. Czirr and Anatole A. Klyosov on July 10, 2000 and is headquartered in Norcross, GA.

Galectin Therapeutics Inc

GALT is trending as traders discuss trading halts on some platforms, potential manipulation, and the possible implications for shorts; the community speculates this could be related to upcoming news or a potential short squeeze. Chatter about brokerages restricting buying has fueled speculation, while others point to the strong science and data presented as a positive catalyst. Discussions about a potential buyout continue, with many closely watching for FDA feedback.

Fluence Energy, Inc. engages in energy storage products and services, and artificial intelligence-enabled digital applications for renewables and storage. The company was founded on June 21, 2021, and is headquartered in Arlington, VA.

Fluence Energy Inc - Ordinary Shares - Class A

Fluence Energy ($FLNC) is trending following Q4 earnings and fiscal year 2026 guidance, with the community highlighting record order intake and backlog growth, signaling strong expansion in the BESS (Battery Energy Storage Systems) market. Bullish sentiment is fueled by the company's outlook, with many believing revenue guidance will be surpassed. Discussions also involve potential benefits from domestic content strategies and increased demand driven by AI and data centers.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and the FC SAN business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom is trending due to positive sentiment around its role in AI infrastructure, particularly following Google's Gemini 3 model announcement and news of potential Saudi investment in AI chips. Community members are weighing AVGO's AI prospects against those of competitors like NVDA, with some highlighting Broadcom's custom chip advantage and attractive dividend yield, while others point to a potential overvaluation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>UBS said that it believes Micron's cycle will be more durable this time as high-bandwidth memory "crowds out" the traditional memory market.</li><li>The firm added that most, if not all, of the industry's capacity additions through 2027 will likely be directed toward high-bandwidth memory.</li><li>Retail sentiment on Micron remained unchanged in the ‘bullish’ territory, with message volumes at ‘high’ levels, according to data from Stocktwits.</li></ul>Micron Technology (MU) became the top trending ticker on Stocktwits after UBS raised its price target on the stock to $275 from $245 and noted that the company is likely tracking above the high end of its guidance.UBS maintained a ‘Buy’ rating on the shares, according to TheFly. The firm said that its recent channel checks indicate "tight" supply conditions persist. Shares of Micron were down nearly 9% in early trading on Thursday.Despite the lack of a positive preannouncement, Micron is likely tracking above the high end of its guidance with double data rate five contract negotiations now edging toward up 20% quarter-over-quarter or higher, UBS noted.UBS said that it believes Micron's cycle will be more durable this time as high-bandwidth memory "crowds out" the traditional memory market. Most, if not all, of the industry's capacity additions through 2027 will likely go to high-bandwidth memory, the firm added.<h2 class="st-heading-2">Semiconductor Tariffs</h2>On Wednesday, according to a Reuters report, U.S. officials are privately saying that they might not levy the long-promised semiconductor tariffs soon. The report, citing people with knowledge of the matter, noted that officials relayed these messages over the last several days to stakeholders in the government and private industry.The report added that the Trump administration is trying not to provoke China and is taking a cautious stance. The news comes as a heave of relief for several companies in the space, including AMD (AMD), Intel (INTC), Marvell (MRVL), Micron (MU) and Nvidia (NVDA), among others.<h2 class="st-heading-2">What Is Retail Thinking?</h2>Retail sentiment around Micron remained unchanged in the ‘bullish’ territory, with message volumes at ‘high’ levels, according to data from Stocktwits.A user on Stocktwits noted that Micron has signed contracts for years with significant growth and revenue, adding that UBS’ $275 price target “is very conservative.”<stembedurl>https://stocktwits.com/84Hawk/message/636918185</stembedurl><a href="https://stocktwits.com/symbol/MU">Shares of Micron</a> have gained over 150% this year.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/bbwi-stock-cracks-premarket-ceo-warns-of-softer-q3/cLPAKD6REa5">BBWI Stock Cracks After CEO Warns Of Tough Holiday Quarter, Slashes Full-Year Guidance</a>

 The logo for Micron Technology is posted at their headquarters on June 25, 2025 in San Jose, California. 

Micron Stock Draws Investor Attention Following A Price Target Boost From UBS 

UBS maintained a ‘Buy’ rating on the shares and noted that its recent channel checks indicate "tight" supply conditions persist.

Equity

<ul class="summary-bullets"><li>The company said that the late-stage study of Mitapivat in patients with sickle cell disease met the primary endpoint of hemoglobin response.&nbsp;</li><li>The drug also yielded positive outcomes on change from baseline in hemoglobin concentration and indirect bilirubin levels compared with placebo.&nbsp;</li><li>While Mitapivat also showed a reduction in the primary endpoint of annualized rate of sickle cell pain crises compared to placebo, this trend did not achieve statistical significance, the company noted.</li></ul>Shares of Agios Pharmaceuticals, Inc. (AGIO) slumped 48% on Wednesday after the company reported mixed results from its drug trial in sickle cell disease.Sickle cell disease is an inherited blood disorder where red blood cells become rigid, sickle-shaped, and unable to flow easily through blood vessels, causing pain and organ damage. The condition leads to complications like painful episodes or crises, anemia, infections, stroke, and damage to organs.<h2 class="st-heading-2">What Did The Study Show?</h2>The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/11/19/3190791/31990/en/Agios-Announces-Topline-Results-from-RISE-UP-Phase-3-Trial-of-Mitapivat-in-Sickle-Cell-Disease.html">said</a> that the late-stage study of Mitapivat in patients aged 16 years and older with sickle cell disease met the primary endpoint of hemoglobin response, with the drug demonstrating a statistically significant improvement compared to placebo. Hemoglobin response is defined as an increase from baseline in average hemoglobin by more than or equal to 1.0 g/dL.The drug also showed positive effects on changes from baseline in hemoglobin concentration and indirect bilirubin levels compared with placebo.While Mitapivat also showed a reduction in the primary endpoint of annualized rate of sickle cell pain crises (SCPCs) or acute pain needing medical contact compared to placebo, this trend did not achieve statistical significance, the company noted. Further, there were no improvements from baseline on fatigue scores among patients, the company noted.The firm now expects to share the comprehensive results from the clinical program with the FDA in the first quarter of 2026 and seek potential U.S. regulatory approval.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/AGIO">AGIO stock</a> jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume increased from ‘high’ to ‘extremely high’ levels.AGIO stock is down by 28% this year and by 57% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/kzia-stock-soars-after-company-stage-iv-cancer-patients-shows-initial-complete-remission-on-its-drug-combination/cLPoQdMREBN">KZIA Stock Soars After Stage IV Cancer Patient Shows Initial Complete Remission On Its Drug Combination</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, the Agios Pharmaceuticals logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

AGIO Stock Cracks After Sickle-Cell Disease Drug Delivers Mixed Results In Late-Stage Trial 

 Sickle cell disease is an inherited blood disorder where red blood cells become rigid, sickle-shaped, and unable to flow easily through blood vessels, causing pain and organ damage.

<ul class="summary-bullets"><li>Olema’s lead product candidate, Palazestrant, belongs to the same class of drugs as Roche’s and is being studied in breast cancer.&nbsp;</li><li>Oppenheimer raised its price target on Olema Oncology to $45 from $22 and kept an ‘Outperform’ rating on the shares.&nbsp;</li><li>The analyst’s new price target implies about a 428% upside from the stock’s Monday closing price.</li></ul>Shares of Olema Pharmaceuticals Inc. (OLMA) more than doubled Tuesday morning on the heels of Roche announcing positive results from its late-stage trial in breast cancer.Roche was <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.roche.com/media/releases/med-cor-2025-11-18">evaluating</a> Giredestrant as an adjuvant endocrine treatment for people with certain types of early-stage breast cancer. In the study, Giredestrant treatment showed a statistically significant and clinically meaningful improvement in invasive disease-free survival compared with standard-of-care endocrine therapy.Giredestrant is an investigational, oral, selective oestrogen receptor degrader or SERD. According to Roche, this is the first late-stage study of a SERD to demonstrate a significant benefit in the adjuvant setting.<h2 class="st-heading-2">Expert Take</h2>As per Oppenheimer, Olema shares were trading pre-market on news that Roche's (RHHBY) trial met its primary endpoint. The analyst subsequently raised its price target on Olema Oncology to $45 from $22 and kept an ‘Outperform’ rating on the shares.The analyst’s new price target implies about a 428% upside from the stock’s Monday closing price.Oppenheimer said it was not expecting this readout, as the entire narrative has been around Roche's different breast cancer clinical trials. Nonetheless, the data are a welcome surprise, it added.Early breast cancer is a multi-billion-dollar market, and one that the firm did not have in its model. These data also incrementally derisk another Roche drug trial, which is testing oral SERDS against aromatase inhibitors in the frontline metastatic setting, Oppenheimer added.Olema’s lead product candidate, Palazestrant, is also a SERD being investigated in patients with recurrent, locally advanced, or metastatic forms of breast cancer. It is being evaluated as a single agent in a late-stage trial and in combination with ribociclib in another late-stage trial.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/OLMA">OLMA stock</a> jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:622/59;" src="data:image/png;base64,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" width="622" height="59" alt="OLMA's Sentiment Meter and Message Volume as of 9:46 a.m. ET on Nov. 18, 2025 | Source: Stocktwits"><figcaption>OLMA's Sentiment Meter and Message Volume as of 9:46 a.m. ET on Nov. 18, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user expressed pessimism about the stock, noting that the hype had passed by pre-market hours, when the stock was up over 200%.<stembedurl>https://stocktwits.com/ChannelRed/message/636586904</stembedurl>Another user, however, believes the stock will touch $100.<stembedurl>https://stocktwits.com/murphylaw/message/636586451</stembedurl>OLMA stock is up by 233% this year and by 125% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/zymeworks-shifts-to-royalty-driven-model-approves-125-m-buyback-plan/cLPVdKtRE7F">Zymeworks Shifts To Royalty-Driven Model From Licensed Drugs, Approves $125M Buyback Plan</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Rising stock market chart on a trading board background.

OLMA Stock Doubles After Roche Cancer Drug Trial Yields Positive Results

Roche was evaluating Giredestrant as an adjuvant endocrine treatment for people with certain types of early-stage breast cancer.

In this photo illustration, the Scholar Rock Holding logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Why Did Scholar Rock Soar 26% Today?

The company is planning to reapply for approval of a muscle atrophy therapy in the coming year. 

<ul class="summary-bullets"><li>Macdonald said that Uber expects to deploy robotaxis on its Uber app across 10-plus cities by this time next year.</li><li>The Uber COO also noted that Uber’s partners outside of the US, such as Chinese robotaxi players WeRide and Pony AI, are starting to lower their costs.</li></ul> Uber Technologies (UBER) COO Andrew Macdonald believes the hardware cost for autonomous vehicles has to come down before they can be financially viable, though technological advancement in the field is significant.Uber has partnerships in place with multiple robotaxi companies, including Pony AI, WeRide and Alphabet Inc’s Waymo. The company is now looking to scale deployments across multiple cities and geographical regions where these robotaxis will be deployed alongside human drivers.“Writing L4 software that’s fully capable of driving on its own safely — and not just as safe as a human, but 10x as safe as a human — I venture to say that problem is almost largely solved,” Macdonald <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.youtube.com/live/e7ZUU9HoJOw?t=23982s">said</a> at the Web Summit 2025 conference in Lisbon on Tuesday.<h2 class="st-heading-2">Hurdles To Cross</h2>However, despite the technological advancement, there are still real problems with commercialization, such as safety record, supportive regulatory frameworks and questions regarding asset ownership and infrastructure, he noted.“...at the end of the day, these are going to be expensive assets for some time and the return on an expensive asset is always going to be driven by utilization,” he noted. &nbsp;According to Macdonald, in Austin, Texas, the average Waymo robotaxi deployed on Uber is busier than 99% of the drivers in the company. However, challenges regarding costs persist, preventing robotaxis from fully replacing human-driven ride-hailing services.“...challenge is that the underlying hardware is still quite expensive and your operating costs in the form of all the pieces of the deployment structure that I talked about are still significant, so the economics don't work today. I think what you need to see is the hardware cost come down. It probably needs to go somewhere from a half to a quarter of where it is today,” he noted.<h2 class="st-heading-2">Cost Reduction Efforts</h2>Macdonald, however, also noted that Uber’s partners outside of the US, such as Chinese robotaxi players WeRide and Pony AI, are starting to lower their costs.“The Chinese automotive sector has a proven track record of being able to iterate and have great tech but also bring the cost of that tech way down with scale. And so it's gonna happen,” he said.Macdonald said that Uber expects to deploy robotaxis on its Uber app across 10-plus cities by this time next year. Currently, the company has deployed robotaxis on its app across about four cities.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/UBER">UBER stock</a> stayed within the ‘bearish’ territory over the past 24 hours, while message volume fell from ‘normal’ to ‘low’ levels.<figure class="image"><img style="aspect-ratio:621/64;" src="data:image/png;base64,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" width="621" height="64" alt="UBER's Sentiment Meter and Message Volume as of 7:39 a.m. ET on Nov. 12, 2025 | Source: Stocktwits"><figcaption>UBER's Sentiment Meter and Message Volume as of 7:39 a.m. ET on Nov. 12, 2025 | Source: Stocktwits</figcaption></figure>UBER stock is up by 57% this year and by about 32% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/cormedix-stock-soars-pre-market-after-earnings-beat-higher-full-year-guidance/cLPIUcNREdG">Cormedix Stock Soars Pre-Market After Earnings Beat, Higher Full-Year Guidance</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Andrew Macdonald, President & COO, Uber, and Craig Trudell, Global Automotive Editor, Bloomberg, on Centre stage during day one of Web Summit 2025 at the MEO Arena in Lisbon, Portugal. (Photo By Alex Broadway/Sportsfile for Web Summit via Getty Images)

Uber COO Says Robotaxi Tech Is Largely Ready But Hardware Costs Are Still Too High

Uber has partnerships in place with multiple robotaxi companies, including Pony AI, WeRide and Alphabet Inc’s Waymo.

<ul class="summary-bullets"><li>For the third quarter, the company reported net revenue of $104.3 million, up from the $11.5 million reported in the corresponding quarter of 2024.</li><li>The growth in revenue was driven by higher-than-expected utilization of DefenCath by outpatient dialysis customers, the company said.</li><li>Adjusted earnings before interest, taxes, depreciation and amortization in Q3 came in at $71.9 million, above an expected $40.65 million.</li></ul>&nbsp;Shares of CorMedix Inc. (CRMD) soared 9% in the pre-market session on Wednesday after the company raised its full-year revenue guidance on the heels of upbeat Q3 earnings.The company now <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/11/12/3186117/0/en/CorMedix-Inc-Reports-Third-Quarter-2025-Financial-Results-and-Updates-FY-2025-Guidance.html">expects</a> pro forma net revenue for the full year in a range of $390 million to $410 million, up from its September guidance of $325 to $350 million and higher than a Wall Street estimate of $283.66 million. &nbsp;Fully synergized pro forma adjusted earnings before interest, taxes, depreciation and amortization for 2025 are now expected in a range of $220 – $240 million, higher that the previously estimated $165 million – $185 million.<h2 class="st-heading-2">Q3 Numbers Beat Wall Street Expectations</h2>For the third quarter, the company reported net revenue of $104.3 million, up from the $11.5 million reported in the corresponding quarter of 2024, and above an analyst estimate of $86.02 million.The growth in revenue was driven by higher-than-expected utilization of DefenCath by outpatient dialysis customers, the company said. DefenCath is an FDA-approved catheter lock solution used to reduce catheter-related bloodstream infections in adult patients undergoing chronic hemodialysis through a central venous catheter. It contributed about 85% of the company’s net revenue in the quarter, the company noted.Adjusted earnings before interest, taxes, depreciation and amortization in Q3 came in at $71.9 million, above an expected $40.65&nbsp;&nbsp;&nbsp;&nbsp; million.Diluted earnings per share in the quarter was at $1.26, above an expected $0.63.<h2 class="st-heading-2">Melinta Therapeutics Acquisition</h2>Cormedix completed the acquisition of Melinta for an upfront consideration of $300 million on August 29. The company now expects synergy capture of approximately $30 million, of the total estimated $35 – $45 million, on an annual run-rate basis before the end of 2025.Sales of Melinta’s portfolio of anti-infective products also aided Cormedix’s revenue in the third quarter.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/CRMD">CRMD stock</a> jumped from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘normal’ levels.CRMD stock is up by 38% this year but down by 4% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/general-motors-races-to-decouple-supply-chain-from-china-report/cLPIHl2RE5r">General Motors Races To Decouple Supply Chain From China: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Cormedix Stock Soars Pre-Market After Earnings Beat, Higher Full-Year Guidance 

The company now expects pro forma net revenue for the full year in a range of $390 million to $410 million, higher than a Wall Street estimate of $283.66 million.  

<ul class="summary-bullets"><li>The deal could reportedly focus on Getir’s delivery business and be valued at as much as $1 billion.</li><li>Bloomberg added that there is no certainty that the talks will lead to a deal.&nbsp;</li><li>The move comes as Uber seeks to expand its delivery business into grocery and retail, away from just food. &nbsp;</li></ul>Uber Technologies Inc. is reportedly in talks with grocery delivery service Getir for a potential deal to expand its delivery operations in Turkey.Bloomberg <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-11-06/uber-said-to-eye-getir-deal-to-expand-in-turkish-delivery-market">reported</a> on Thursday, citing people familiar with the matter, that Uber has been holding preliminary discussions with Getir investor Mubadala Investment about acquiring key parts of the Turkish company.The deal could focus on Getir’s delivery business and be valued at up to $1 billion, the report said. However, the deal value depends on the assets that will ultimately be included in the transaction, the report noted, while also adding that there is no certainty that the talks will lead to a deal.The report also noted that Mubadala is considering selling Getir’s finance business separately. Getir restructured its business last year and closed its overseas operations.<h2 class="st-heading-2">Uber’s Delivery Push</h2>The move comes as Uber seeks to expand its delivery business into grocery and retail, away from just food.Earlier this week, the company reported that its third-quarter revenue increased 20% to $13.5 billion, primarily due to growth in the company’s mobility and delivery businesses. While revenue from the company’s delivery segment rose 29% to $4.5 billion in the quarter, revenue from the mobility segment grew 20% to $7.7 billion, even as freight division revenue remained flat year-on-year.Uber CEO Dara Khosrowshahi said on the company’s earnings call that its ambitions “go well beyond meals.” He added that its grocery and retail business is already approaching a $12 billion Gross Bookings run-rate and is growing significantly faster than food delivery.“As consumers engage more with G&amp;R, they use Uber more broadly and stay with us longer,” he added.<h2 class="st-heading-2">How Did Stocktwits User React?</h2>On Stocktwits, retail sentiment regarding <a href="https://stocktwits.com/symbol/UBER">Uber stock</a> remained in the 'extremely bullish' territory over the past 24 hours, while message volume remained at 'extremely high' levels.UBER stock is up by 52% this year and by about 23% over the past 12 months.Also See:<a href="https://stocktwits.com/news-articles/markets/equity/fdmt-stock-gains-pre-market-after-positive-study-data-for-experimental-drug-in-eye-disease/cL2tFCrREbU"> FDMT Stock Gains Pre-Market After Positive Study Data For Experimental Drug In Eye Disease</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, the Uber Technologies Inc logo is seen displayed on a smartphone screen. 

Uber In Talks With Getir To Expand Delivery Services In Turkey: Report

Bloomberg reported on Thursday, citing people familiar with the matter, that Uber has been holding preliminary discussions with Getir investor Mubadala Investment about acquiring key parts of the Turkish company. 

<ul class="summary-bullets"><li>4D-150 demonstrated consistent and durable benefits in patients with wet age-related macular degeneration in the study.&nbsp;</li><li>The company is currently enrolling patients into late-stage trials for the drug.</li><li>Enrollment is continuing ahead of initial projections, CEO David Kirn said. &nbsp;</li></ul>4D Molecular Therapeutics (FDMT) announced on Thursday that its experimental drug 4D-150 demonstrated consistent and durable benefits in patients with wet age-related macular degeneration in an early-to-mid-stage trial.Wet age-related macular degeneration (AMD) is an advanced form of macular degeneration where abnormal blood vessels grow in the retina, leak fluid or blood, and cause a rapid decline in central vision. The proliferation and leakage of abnormal blood vessels is stimulated by vascular endothelial growth factor (VEGF), a protein that promotes the growth of new blood vessels. According to 4D, the disease has a high incidence, with 200,000 individuals estimated to be newly diagnosed every year in the U.S. alone.<h2 class="st-heading-2">Study Findings</h2>4D-150 showed maintenance of visual acuity and control of retinal anatomy in the study, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.4dmoleculartherapeutics.com/news-releases/news-release-details/4dmt-announces-positive-long-term-data-phase-12-prism-clinical">said</a>. The study also reduced treatment burden as patients maintained a consistent and clinically meaningful reduction in supplemental injections in 6-month intervals following dosing with 4D-150 through up to two years of follow-up, it added.4D-150 was further well tolerated with no new safety or intraocular inflammation findings. The drug is aimed at providing multi-year, and potentially lifelong, sustained delivery of anti-VEGF from the retina with a single, safe, intravitreal injection. Anti-VEGF is a treatment that blocks the action of the vascular endothelial growth factor.The company is currently enrolling patients into late-stage trials for the drug. Enrollment is continuing ahead of initial projections, according to CEO David Kirn.“With the robust PRISM dataset and our APAC region strategic partnership with Otsuka announced last week, we are well positioned for global success in our Phase 3 4FRONT clinical trials, which continue to enroll ahead of initial projections,” he added. &nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Shares of the company soared 13% in the pre-market session at the time of writing. On Stocktwits, retail sentiment regarding <a href="https://stocktwits.com/symbol/FDMT">FDMT stock</a> remained within the ‘bullish’ territory, while message volume remained at ‘high’ levels over the past 24 hours.FDMT stock is up 89% this year and approximately 26% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/dupont-announces-2-billion-share-buyback-stock-tumble-7-today/cL2t8hLREbz">DuPont Announces $2 Billion Share Buyback: Why Did The Stock Tumble 7% Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Global stock market chart and trading board - stock photo

FDMT Stock Gains Pre-Market After Positive Study Data For Experimental Drug In Eye Disease

The drug showed maintenance of visual acuity, control of retinal anatomy, and reduction of treatment burden at all time points with up to 2 years of follow-up. 

<ul class="summary-bullets"><li>Biohaven was seeking approval for its drug Vyglxia in the treatment of Spinocerebellar ataxia.&nbsp;</li><li>The company is in the process of formally requesting a meeting as soon as possible to determine the potential next steps.</li><li>Biohaven added that it may pause or delay non-priority programs to maintain its cash runway in the near term.&nbsp; &nbsp;</li></ul>Shares of Biohaven (BHVN) slumped 44% in the premarket session on Wednesday after the U.S. Food and Drug Administration refused to approve its drug Vyglxia in the treatment of Spinocerebellar ataxia (SCA).Spinocerebellar ataxia is a neurodegenerative disorder characterized by progressive loss of voluntary motor control and atrophy of the brain’s cerebellum and brainstem. According to Biohaven, the condition affects approximately 15,000 people in the United States, but there are currently no FDA-approved treatments available.<h2 class="st-heading-2">What Did The FDA Say?</h2>In a <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.biohaven.com/news-releases/news-release-details/fda-issues-complete-response-letter-biohavens-vyglxia">letter</a>, the FDA cited issues including potential bias, design flaws, lack of pre-specification, and unmeasured confounding factors in Biohaven’s drug studies. The agency also recommended that the company meet with the agency to discuss the evidence that will be needed to support a future application.Biohaven is in the process of formally requesting a meeting as soon as possible to determine the potential next steps.<h2 class="st-heading-2">Biohaven’s Response</h2>Biohaven CEO Vlad Coric expressed disappointment over the FDA decision. “There are a number of common sense solutions and regulatory tools that the (FDA’s) Office of Neuroscience could have applied including a fair hearing of the drug's efficacy and safety risks at an Advisory Committee of experts and patients, post-marketing studies, labelling limitations or an accelerated approval pathway,” he said.<h2 class="st-heading-2">Steps Forward</h2>In the meantime, Biohaven said it will prioritize resources to focus all its research and development resources on other key programs in its portfolio.Over the next year, the company will focus on three late-stage, clinical programs with the greatest potential for value generation. It has also initiated strategic portfolio and cost optimization across multiple programs to achieve an approximately 60% reduction in annual direct research and development spend.The company added that it may pause or delay non-priority programs to maintain its cash runway.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/BHVN">BHVN stock</a> stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:622/57;" src="data:image/png;base64,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" width="622" height="57" alt="BHVN's Sentiment Meter and Message Volume as of 7:12 a.m. ET on Nov. 5, 2025 | Source: Stocktwits"><figcaption>BHVN's Sentiment Meter and Message Volume as of 7:12 a.m. ET on Nov. 5, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expressed hopes for the pipeline.<stembedurl>https://stocktwits.com/Dheeraj_6/message/634978290</stembedurl>BHVN stock is down 63% this year and approximately 73% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/why-upstart-stock-is-plunging-over-14-premarket-today/cL2qgqXREGX">Why Upstart Stock Is Plunging Over 14% Premarket Today</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Biohaven logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

BHVN Stock Tumbled A Whopping 44% Today – What Did The FDA Letter Say?

The FDA cited issues including potential bias, design flaws, lack of pre-specification, and unmeasured confounding factors in Biohaven’s Vyglxia studies to refuse drug approval. 

The FDA cited issues, including potential bias, design flaws, lack of pre-specification, and unmeasured confounding factors in Biohaven’s Vyglxia studies to refuse drug approval. 

<ul class="summary-bullets"><li>William Blair downgraded Fiserv to ‘Market Perform’ from ‘Outperform’ and noted that it no longer recommends the stock, given a "shocking" third quarter.</li><li>Wolfe Research downgraded Fiserv to ‘Peer Perform’ from ‘Outperform,’ according to TheFly, on the heels of the guidance cut that it says "raised structural concerns."</li><li>Fiserv announced that Paul Todd has been named the company’s Chief Financial Officer, effective October 31, succeeding Robert Hau.</li></ul>Fiserv Inc. (FI) shares were down nearly 44%,&nbsp;on track for&nbsp;their largest one-day decline on Wednesday, as the company also witnessed multiple Wall Street downgrades following leadership transitions and a cut in annual forecasts.Wolfe Research downgraded Fiserv to ‘Peer Perform’ from ‘Outperform,’ according to TheFly on the heels of the guidance cut that it says "raised structural concerns." The firm noted that it was "tactically cautious" and previewed a potential guidance cut.The firm said that the combination of materially weaker third-quarter results across segments, along with acknowledgement of several short-term and unsustainable levers used at the company in recent years that need to be reversed, led Wolfe Research to see "too much uncertainty in the medium-term through a necessary transition period.”The company stock fell about 44%, hitting its biggest percentage drop ever at $71.22, according to Koyfin. Retail sentiment on Fiserv jumped to ‘extremely bullish’ from ‘bearish’ territory compared to a day ago, with message volumes at ‘extremely high’ levels, according to data from Stocktwits.<h2 class="st-heading-2">William Blair Calls It A “Shocking Q3”</h2>William Blair downgraded Fiserv to ‘Market Perform’ from ‘Outperform,’ according to TheFly. The firm noted that it no longer recommends the stock given a "shocking" third-quarter revenue and earnings per share miss and abrupt management transition.Relatively new CEO Mike Lyons is now in a difficult position to figure out what went wrong, the firm noted, adding that it has "low conviction" in the underpinnings of Fiserv's merchant competitive position.On Wednesday, the company announced that Paul Todd has been named the company’s Chief Financial Officer, effective October 31, succeeding Robert Hau, who will serve as a senior advisor through the first quarter of 2026.<h2 class="st-heading-2">Buying Opportunity In Fiserv Peers</h2>Wells Fargo said that it sees buying opportunities in Fiserv, Global Payments (GPN), Block (XYZ) and Toast (TOST) with the stocks trading down in sympathy with Fiserv.Fiserv's issues are largely company-specific and execution related, which is likely benefitting its peers, Wells Fargo said. As such, the firm said it believes read-throughs from the company's earnings report to peers are "misguided" and still expects FIS, Global Payments, Block and Toast to report solid results.<a href="https://stocktwits.com/symbol/FI">Shares of Fiserv</a> have declined over 65% this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/caterpillar-sees-strong-growth-in-energy-segment-fueled-by-ai-infrastructure-demand/cLGZsDmR3wD">Caterpillar Sees Strong Growth In Energy Segment Fueled By AI Infrastructure Demand</a>

In this photo illustration, the Fiserv company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Fiserv Shares Plunge 44% In Record One-Day Drop As Company Gets Wall Street Downgrades On Leadership Changes, Forecast Cuts

Wolfe Research downgraded Fiserv to ‘Peer Perform’ from ‘Outperform,’ according to TheFly, on the heels of the guidance cut that it says "raised structural concerns."

Vanguard Group, Inc. - Vanguard U.S. Momentum Factor ETF

Buying

Holding

Selling or trimming

Watching from the sidelines

What are you doing with Alphabet ($GOOGL) stock as it hits fresh all-time highs?

VFMO
Vanguard Group, Inc. - Vanguard U.S. Momentum Factor ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest VFMO News

VFMOVanguard Group, Inc. - Vanguard U.S. Momentum Factor ETF